Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

SELL
$7.78 - $14.69 $389,000 - $734,500
-50,000 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$11.38 - $16.4 $569,000 - $819,999
50,000 New
50,000 $666,000

Others Institutions Holding MYOV

About Myovant Sciences Ltd.


  • Ticker MYOV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 96,802,800
  • Description
  • Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...
More about MYOV
Track This Portfolio

Track Resolute Capital Asset Partners LLC Portfolio

Follow Resolute Capital Asset Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Resolute Capital Asset Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Resolute Capital Asset Partners LLC with notifications on news.